Abstract
Background/aim Immune thrombocytopenia (ITP) is treated by corticosteroids and/or intravenous immune globulin as the first line treatment when necessary. Mean platelet volume (MPV) is a marker of platelet production and function. In this study, we aimed to search the relationship between the MPV and the treatment response in ITP patients and it was hypothesized that MPV can be used as a predictor of the response.Materials and methods The 70 newly diagnosed adult primary ITP patients and 70 of healthy people were included. MPV between ITP and healthy population, MPV in the diagnosis and after the treatment between the responders and the nonresponders were compared. ResultsThe responders had significantly higher MPV and the nonresponders had significantly lower MPV than the healthy population (11.09 and 10.21 fL, P = 0.03; 9.38 and 10.21 fL, P = 0.001). MPV in the diagnosis was significantly higher in the responders than the nonresponders (11.09 and 9.38 fL, P = 0.005). MPV significantly changed after the treatment in the responders (11.09 to 9.32 fL, P = 0.004). ConclusionMPV can be used as a predictor of early response to the first line treatment in newly diagnosed adult primary ITP patients.
Highlights
Mean platelet volume (MPV) can be used as a predictor of early response to the first line treatment in newly diagnosed adult primary Immune thrombocytopenia (ITP) patients
Immune thrombocytopenia (ITP) is an acquired thrombocytopenia which is defined by the platelet count (PLT) is less than 100 × 109/L
Due to the immune pathophysiological mechanism of the primary ITP, patients are initially treated by corticosteroids and intravenous immune globulin (IVIG), when they need the treatment [1]
Summary
Immune thrombocytopenia (ITP) is an acquired thrombocytopenia which is defined by the platelet count (PLT) is less than 100 × 109/L. Due to the immune pathophysiological mechanism of the primary ITP, patients are initially treated by corticosteroids and intravenous immune globulin (IVIG), when they need the treatment [1]. The platelet count increases in 3–5 days after the treatment, there is no available study that may investigate the predictive factors of the short-term response to the first line therapy. Several studies have investigated the MPV value in the diagnosis and differential diagnosis of the ITP and hypoproliferative thrombocytopenia [3,4,5,6,7,8], relapse of the ITP [9,10] and thrombocytosis [11].
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
